Press releases
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Key statistics
As of last trade SAGE Therapeutics Inc (SG7:FRA) traded at 10.51, 3.50% above its 52-week low of 10.16, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.51 |
---|---|
High | 10.51 |
Low | 10.51 |
Bid | 10.58 |
Offer | 10.92 |
Previous close | 10.86 |
Average volume | 166.67 |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 717.97m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of May 29 2024 07:46 BST.
More ▼